Interleukin 23 (IL-23) is integral to the pathogenesis of chronic inflammation. The resolution of acute inflammation is an active process mediated by specific signals and mediators such as resolvin E1 (RvE1). Here we provide evidence that RvE1, in nanogram quantities, promoted the resolution of inflammatory airway responses in part by directly suppressing the production of IL-23 and IL-6 in the lung. Also contributing to the pro-resolution effects of RvE1 treatment were higher concentrations of interferon-c in the lungs of RvE1-treated mice. Our findings indicate a pivotal function for IL-23 and IL-6, which promote the survival and differentiation of IL-17-producing T helper cells, in maintaining inflammation and also identify an RvE1-initiated resolution program for allergic airway responses.
Asthma is a chronic inflammatory disease of the airways characterized by infiltration of eosinophils and T lymphocytes that produce cytokines and proinflammatory lipid mediators, such as leukotrienes, which contribute to disease severity 1,2 . The incidence of asthma is increasing in Western countries 1 . Approximately 5% of people with asthma suffer from severe disease that is refractory to the medical treatment available at present 3 . Notably, no therapy is available to actively resolve the aberrant immune responses in asthmatic patients.
Epidemiological studies have indicated that diets rich in omega-3 fatty acids are associated with lower asthma prevalence 4 ; however, the mechanisms underlying this observation remain unclear. Resolvins are products of omega-3 fatty acids named on the basis of their original identification in resolving exudates and their ability to exert potent anti-inflammatory properties to accelerate the resolution phase of acute peritoneal inflammation [5] [6] [7] [8] . Resolvin E1 (RvE1) is a potent inhibitor of the transmigration of polymorphonuclear leukocytes across endothelial and epithelial barriers and promotes the clearance of apoptotic polymorphonuclear leukocytes and microbial products by macrophages 9, 10 . However, the effect of RvE1 on adaptive immunity is not known.
T H -17 cells, a subset of CD4 + T helper cells characterized by the production of interleukin 17A (IL-17A), have been linked to the pathogenesis of many inflammatory diseases, including arthritis, experimental autoimmune encephalitis, inflammatory bowel disease and airway inflammation 11 . The population expansion and survival of T H -17 cells depend on IL-23, which like IL-17 has been linked to the pathobiology of chronic inflammatory diseases [12] [13] [14] [15] . IL-17 is present in asthmatic airways and can induce lung inflammation and stimulate mucus production [16] [17] [18] [19] [20] [21] [22] [23] . Here we have investigated the effect of RvE1 on allergic airway inflammation in an experimental model of asthma. RvE1 both dampened the development and promoted the resolution of airway inflammation, in part by inhibiting the release of IL-23 from dendritic cells (DCs).
RESULTS

RvE1 impairs the development of airway inflammation
Mouse experimental models of asthma involve allergen sensitization and airway challenge 24 . There is little information on the time course of the natural resolution of allergic airway inflammation after discontinuation of allergen airway challenge. To determine the kinetics of the spontaneous resolution of allergic lung inflammation, we monitored airway leukocyte numbers in bronchoalveolar lavage fluid (BALF) at 1, 4 and 8 d after the final of four daily allergen aerosol challenges. These time points corresponded to protocol days 18, 21 and 25 (Fig. 1a) . Significant decrements in total BALF cell numbers were evident, with a decrease of about 27% between days 18 and 21 and a further decrease of about 60% between days 21 and 25, (Fig. 1b) . There was a distinct temporal regulation for each class of leukocyte (Fig. 1c) . Similar to total leukocytes, eosinophils decreased by about 25% between days 18 and 21 and about an additional 70% by day 25. In contrast, macrophages decreased by about 35% between days 18 and 21, but no significant further decrease was evident by day 25. Notably, lymphocytes increased significantly between days 18 and 21 and then decreased substantially by about 85% by day 25. These findings indicate that the natural resolution of inflammatory cell trafficking in the airway is an active and highly regulated process.
Because diets rich in eicosapentaenoic acid are linked to lower asthma prevalence 4 and the eicosapentaenoic acid-derived RvE1 regulates acute inflammatory responses 10 , we next determined the effect of RvE1 on inflammatory cell trafficking in allergic airway inflammation. The administration of RvE1 (200 ng/d given intravenously) 30 min before challenge with ovalbumin (OVA) on protocol days 14-17 ( Fig. 1a) resulted in significantly lower BALF leukocyte numbers at day 18, about 80% lower than those of mice exposed to vehicle (0.1% ethanol; Fig. 1d ). The numbers of BALF eosinophils, macrophages and lymphocytes were all considerably lower after RvE1 treatment (Fig. 1e) . These findings indicate that RvE1 can prevent the development of allergic airway inflammation. Of note, endogenous concentrations of RvE1 in normal and inflamed mouse lungs were below the limits of detection by liquid chromatography-tandem mass spectrometry.
RvE1 promotes the resolution of airway inflammation
As the findings reported above showed potent immunomodulatory actions of RvE1, and given the absence of 'pro-resolution' therapies for asthma, we next determined the influence of RvE1 on the resolution of established airway inflammation. We administered RvE1 (100 ng/d intravenously) or vehicle (0.1% ethanol) for 3 consecutive days (protocol days [18] [19] [20] after the final allergen challenge and counted BALF leukocytes on days 21 and 25 (Fig. 2a) . On day 21, RvE1-treated mice had significantly fewer total BALF leukocytes, including eosinophils, macrophages and lymphocytes, than did vehicle-treated mice (Fig. 2b,c) . The resolution interval is defined as the time required for cell numbers to reach 50% of the numbers noted at the peak of inflammation 25 . In vehicle-treated mice, between protocol days 18 and 25, the endogenous resolution interval for BALF leukocytes was about 5 d (Fig. 2d) . Notably, the resolution interval for RvE1-treated mice was much shorter, at about 2.5 d. These findings collectively indicate that RvE1 exerts both anti-inflammatory and pro-resolution effects in this model of airway inflammation.
At day 21 in the resolution protocol, histopathological analysis showed much less leukocyte infiltration and adherence to vascular endothelial surfaces and less-reactive bronchial epithelial cells in the lungs of RvE1-treated mice (Fig. 3a,b and Supplementary Fig. 1  online) . In addition, periodic acid-Schiff staining showed that RvE1 also resulted in less production of airway epithelial mucus (Fig. 3c,d) . Thus, in the absence of continued allergen exposure, RvE1 rapidly resolved airway leukocyte infiltration and lung morphological changes associated with allergic inflammation.
Airway hyper-responsiveness is a functional hallmark of asthma 3 . At protocol day 21, we measured airway hyper-responsiveness in anesthetized mice that were mechanically ventilated in the presence of increasing doses of inhaled methacholine. Mice treated with RvE1 showed significant protection from methacholine-induced increases in mean lung resistance (Fig. 3e) . The effective dose of methacholine needed to increase mean lung resistance 200% from baseline was much higher for RvE1-treated mice than for their vehicle-treated counterparts (Fig. 3f) . These results indicate that in addition to inflammation, RvE1 also accelerated the resolution of allergic airway pathology and airway hyper-responsiveness.
RvE1 regulates cytokine and lipid mediators
To identify the mechanisms by which RvE1 regulates airway responses, we measured cytokines and lipid mediators that modulate T cell population expansion and differentiation by cytokine bead array in BALF from vehicle-or RvE1-treated mice at protocol day 21. Notably, treatment with RvE1 resulted in significantly lower IL-17A concentrations, about 70% lower than that of vehicle-treated mice (Fig. 4a) . In control mice sensitized to OVA but challenged with aerosol saline, IL-17A concentrations were undetectable at day 21. The survival and differentiation of T H -17 cells are promoted by the cytokines IL-23 and IL-6, respectively 26 . Administration of RvE1 Fig. 4e-h ). In addition, there was no significant difference in the serum concentration of immunoglobulin E (25.3 ± 2.7 ng/ml for vehicle versus 26.5 ± 3.4 ng/ml for RvE1). Because IL-27 can block the development of both T H 2 and T H -17 inflammatory responses [27] [28] [29] , we also measured IL-27 concentrations in BALF. Treatment with RvE1 resulted in much lower IL-27, about 60% lower than that of vehicle-treatment ( Fig. 4i) , which indicated that RvE1 suppressed T H -17 responses in an IL-27-independent way. These results collectively indicate that RvE1 is a potent and selective regulator of cytokines pivotal for airway inflammation. Given their important functions in inflammation and asthma, we also measured the proinflammatory lipid mediators leukotriene B 4 (LTB 4 ) and cysteinyl leukotrienes in the BALF of vehicle-and RvE1-treated mice 3 . RvE1 treatment led to significantly lower LTB 4 (Fig. 4j) . Notably, endogenous concentrations of the counter-regulatory eicosanoid mediator lipoxin A 4 (LXA 4 ) increased from peak inflammation (64.1 ± 12.9 pg/ml at day 18) to resolution (183.7 ± 31.3 pg/ml at day 21; (mean ± s.e.m.)). RvE1 administration led to even higher LXA 4 concentrations on protocol day 21 (330.00 ± 55.5 pg/ml (mean ± s.e.m.); Fig. 4k ). We found no significant differences in concentrations of the lipid mediator prostaglandin D 2 (954.1 ± 34.0 for vehicle versus 943.5 ± 24.5 pg/ml for RvE1 (mean ± s.e.m.)). These findings collectively identify a 'fingerprint' of selective mediator regulation by RvE1 and suggest that T H -17 cells and LTB 4 may promote maintenance of inflammation in a way distinct from the pathogenic functions of T H 2 cells and cysteinyl leukotrienes in the initiation of allergic inflammatory responses.
RvE1 regulates the production of IL-17 and IFN-c by T cells
To investigate if changes in T cell phenotype were responsible for the changes in the production of IL-17A and IFN-g, we excised lungs, lung-draining mediastinal lymph nodes and spleens on protocol day 21 and measured IL-17A and IFN-g in CD4 + T cells with flow cytometry (Fig. 5a ). The administration of RvE1 (days 18-20) resulted in a significantly higher ratio of CD4 + T cells expressing IFN-g to those expressing IL-17A in all tissues (Fig. 5b) . To determine the effect of IL-17A on the resolution of allergic airway inflammation, we gave mice intranasal administration of an IL-17A-neutralizing antibody (10 mg/d), isotype control antibody or recombinant mouse IL-17 (1 mg/d) each day on protocol days 18-20. Treatment with IL-17A-neutralizing antibody led to significantly lower total numbers of BALF leukocytes, eosinophils and macrophages than those of both vehicleand isotype control-treated mice ( Fig. 5c and Supplementary Fig. 2a online). BALF leukocyte numbers at protocol day 21 after treatment with IL-17A-neutralizing antibody were similar to those noted after RvE1 treatment (Fig. 5c) . The administration of recombinant mouse IL-17A had no significant effect on total BALF leukocytes, but the administration of IL-17A in combination with RvE1 blocked the ability of RvE1 to induce the resolution of leukocyte trafficking, as assessed by leukocyte numbers in BALF ( Fig. 5c and Supplementary Fig. 2a ). The administration of recombinant mouse IL-23 together with RvE1 also blocked the pro-resolution effects of RvE1 ( Fig. 5c and Supplementary Fig. 2b ). As IL-6 promotes T H -17 differentiation 30 and RvE1 resulted in lower IL-6 concentrations in BALF (Fig. 4c) , we examined the effects of exposure to recombinant mouse IL-6 on RvE1-mediated resolution. Notably, like IL-23 and IL-17, IL-6 blocked RvE1-mediated decrements in BALF leukocyte numbers (Fig. 5d) . These findings collectively indicate pivotal functions for IL-23 and T H -17 cells in the persistence of airway inflammation.
To determine if the RvE1-mediated increase in IFN-g (Fig. 4d ) contributed to the pro-resolution actions of RvE1, we gave mice an IFN-g-neutralizing antibody. Relative to treatment with RvE1, antibody to IFN-g (anti-IFN-g) led to significantly more total leukocytes in BALF (Fig. 5d) that were mainly the result of more eosinophils ( Supplementary Fig. 2c ). Mice that received anti-IFN-g together with RvE1 had fewer BALF leukocytes than did mice treated with anti-IFN-g and vehicle but had more BALF leukocytes than did mice treated with RvE1 alone (Fig. 5d) . However, anti-IFN-g did not influence the concentration of IL-23 in BALF; this was similar in mice treated with anti-IFN-g plus RvE1 and those treated with RvE1 alone ( Supplementary Fig. 3 online) . These findings indicate that IFN-g does not regulate IL-23 in this setting but does contribute to RvE1-mediated inflammation resolution. Examination of lung histopathology identified similar trends, as mice treated with anti-IL-17A showed less leukocyte infiltration and hypertrophic changes to the airway epithelium, similar to mice treated with RvE1, and treatment with anti-IFN-g reversed the ameliorative effects of RvE1 (Fig. 5e) . These findings collectively indicate involvement of IL-23, IL-17 and IL-6 in the maintenance of airway inflammation and of IFN-g in its resolution after discontinuation of allergen challenge.
Overlapping yet distinct effects of RvE1 and lipoxin Because LXA 4 concentrations increased during spontaneous resolution (day 21) and RvE1 treatment further increased LXA 4 concentrations (Fig. 4k) , we next investigated the effect on airway inflammation of the LXA 4 analog 15-epi-lipoxin analog (ATLa) alone or in combination with RvE1. This stable analog of lipoxin prevents the development of allergic airway responses 24 , but its influence on resolution in this model has not been determined. ATLa resulted in significantly fewer BALF leukocytes at protocol day 21, by a magnitude similar to that of RvE1 (100 ng/d; Fig. 6a ). We noted no synergistic effect of RvE1 (50 ng) and ATLa (100 ng; Fig. 6a) . Quantification of the concentration of IL-17, IL-23 and IFN-g in BALF showed distinct regulation of these cytokines by RvE1 and ATLa. Both RvE1 and ATLa resulted in significantly lower IL-17 concentrations (Fig. 6b) , but RvE1 resulted in less IL-23 and ATLa did not (Fig. 6c) . In contrast to the RvE1-induced increase in IFN-g, ATLa alone and together with RvE1 resulted in significantly lower IFN-g concentrations (Fig. 6d) .
RvE1 inhibited IL-23 production in vivo and this cytokine can be released by activated DCs 31, 32 . In addition, inflamed lungs removed from mice at protocol day 21, as well as bone marrow-derived DCs (BMDCs), expressed RNA transcripts encoding receptors for RvE1 (ChemR23 and BLT-1) and ATLa (ALX; data not shown). Therefore, we measured the effect of RvE1 on the release of IL-23 from lipopolysaccharide-stimulated BMDCs. RvE1 potently inhibited IL-23 release in a concentration-dependent way (Fig. 6e) . The addition of BOC-2 peptide, an antagonist of the LXA 4 and ATLa receptor ALX 33 , did not block inhibition of the release of IL-23 effected by RvE1. Of note, RvE1 (1 ng/ml) also inhibited the release of IL-6 and tumor necrosis factor from these activated BMDCs (Fig. 6f) . These findings collectively show that LXA 4 and RvE1 both inhibit IL-17 in vivo, yet RvE1 alone regulates IL-23 in vivo and in vitro in an LXA 4 -independent way.
DISCUSSION
Here we have provided evidence that RvE1 acts as an anti-inflammatory and pro-resolution lipid mediator of allergic airway inflammation. After antigen sensitization and aerosol challenge, there was a natural and spontaneous resolution of inflammation in the airway that was accelerated by the administration of nanogram quantities of RvE1. In addition to resolving inflammation, RvE1 also dampened airway mucus and hyper-reactivity, responses typical of asthma. RvE1 resulted in lower concentrations of IL-23, IL-6 and IL-17 and higher IFN-g concentrations; these cytokine alterations were reflected in shifting percentages of T H -17 and IFN-g-producing CD4 + T cells in lung, lung-draining mediastinal lymph nodes and spleen. Antibody neutralization experiments indicated that IL-17A is an essential 'driver' of airway inflammation in vivo. Moreover, the exogenous addition of recombinant IL-23 or IL-6 or a neutralizing antibody to IFN-g prevented RvE1-mediated resolution. RvE1 treatment also resulted in more LXA 4 , and a stable LXA 4 analog shared the proresolution and IL-17-counter-regulating actions of RvE1. These findings collectively indicate that IL-23 and T H -17 cells are essential for the maintenance of airway inflammation and provide evidence of counter-regulatory lipid mediators with the ability to control these proinflammatory cytokines and T cells. IL-23 is involved in the pathobiology of many chronic diseases, including colitis, encephalitis, psoriasis, rheumatoid arthritis and cancer 12, 14, 15, 34 , and it is critical for the survival of T H -17 cells 12, 30 . These T cells release IL-17A, a cytokine that increases the production of several proinflammatory molecules, including IL-1 and tumor necrosis factor 35 . RvE1 resulted in much lower concentrations of IL-6, IL-23 and IL-17A in BALF, which indicates that the pathways promoting the differentiation and survival of T H -17 cells are regulatory checkpoints countered by RvE1 during the resolution of airway inflammation. RvE1 alone regulated IL-23 both in vivo and in vitro. The administration of IL-23 in combination with RvE1 blocked its ability to promote resolution, which indicates that IL-23 is important in prolonging airway inflammation. Notably, eosinophils express the IL-23 receptor and IL-23 induces the release of proinflammatory chemokines from eosinophils 22 . Emphasizing the importance of IL-23 and T H -17 cells in general inflammation, IL-23-deficient mice are protected in models of colitis 13 . Similar to IL-23, RvE1 can also protect against the development of colitis in model systems 36, 37 . Thus, the regulation of IL-23 and T H -17 cells by RvE1 may serve as a common mechanism for its pro-resolution actions in mucosal inflammation.
IL-17 is pivotal in regulating airway inflammation and responses to allergen 20, 21, 38 . The expression in airway epithelium of an IL-17 transgene driven by the promoter of the gene encoding CC10 leads to spontaneous airway inflammation characterized by infiltration of eosinophils and lymphocytes, hypertrophic changes to the epithelium and more mucus production 18 . In addition, mice deficient in the IL-17 receptor do not develop allergen-induced airway inflammation 20 . Moreover, higher concentrations of IL-17 in human BALF and induced sputum are associated with asthma 16, 20, 39 . Notably, IL-17 may have dual regulatory functions in allergic airway inflammation, as it can also inhibit T H 2-driven immune responses 20 . Concurrent administration of allergen and recombinant IL-17 to sensitized animals dampens airway inflammation by decreasing the production of IL-5, IL-13, CCL11 and CCL17 in an IL-4 receptor-dependent way 20 . In contrast, in our experiments here, the concentration of IL-17 in BALF remained higher in established asthma 3 d after allergen exposure. In promoting resolution, RvE1 resulted in significantly lower IL-17 and allergic airway responses. In addition, IL-17-neutralizing antibody resulted in significantly lower BALF leukocyte numbers, and recombinant mouse IL-17 blocked the ability of RvE1 to promote resolution. RvE1 also downregulated IL-6 in BALF in vivo and also in vitro from lipopolysaccharide-stimulated BMDCs. IL-6 is higher in the serum of asthmatic subjects than in nonasthmatic patients 40 , and IL-6 transsignaling through a soluble IL-6 receptor supports T H 2 and T H -17 differentiation 30, 40 . These results collectively indicate that RvE1-mediated regulation of IL-17 is important in promoting the resolution of airway inflammation and suggest a pathogenic relationship between IL-17 and persistent airway inflammation in this model.
In contrast, RvE1 did not have a significant effect on the concentrations of IL-10 and the T H 2 cytokines IL-4, IL-5 and IL-13 during resolution. Thus, when no longer exposed to allergen, the T H -17 cells and cytokines that maintained the inflammatory response exerted effects distinct from the T H 2 cells and cytokines involved in the initiation of allergic inflammatory responses. Of note, RvE1 facilitated resolution despite lower concentrations of IL-27, which can regulate both T H -17 and T H 2 cells [27] [28] [29] .
RvE1 resulted in more production of IFN-g, and T H -17 immune responses are inhibited by IFN-g 18 . IFN-g can contribute to resolution by upregulating expression of the receptor Fas (CD95) on lymphocytes to increase their rate of apoptosis 41 . Mice lacking IFN-g or Fas show defective resolution of inflammation in experimental models of asthma 42, 43 . As an IFN-g-neutralizing antibody partially blocked RvE1-mediated resolution, IFN-g is important for the resolution of airway inflammation in this setting. However, as anti-IFN-g did not result in lower concentrations of IL-23 in BALF, IFN-g promoted resolution by a mechanism distinct from that of RvE1.
ChemR23 is a cognate receptor for RvE1 and is expressed on several immunoregulatory cell types, including DCs 44 . In a model of zymosan-induced peritonitis, ChemR23-deficient mice develop more inflammation, which indicates that this receptor is important for counter-regulatory signaling 45 . Our new findings presented here bolster the emerging idea of resolution as an active process with specific counter-regulatory signaling pathways.
The ideal outcome of resolution of inflammation is complete tissue catabasis 46 . RvE1-mediated increases in the concentration of both IFNg and LXA 4 are indicative of its agonist properties. As an autocoid, RvE1 is rapidly formed, rapidly inactivated and has potent 'bioactions' at subnanomolar concentrations 8 . Although it was difficult to detect in vivo here in inflamed lungs, endogenous RvE1 has been detected in several models of spontaneously resolving inflammation 5, 6 . In addition, RvE1 can be increased by dietary modification, administration of aspirin or transgenic expression of the gene encoding n-3 fatty acid desaturase from Caenorhabditis elegans 36, 37, 44 . Moreover, disruption of the endogenous formation of RvE1 or LXA 4 by biosynthetic enzyme inhibition disrupts the resolution of acute inflammation, resulting in prolonged inflammatory responses 10, 47 . In addition, severe and uncontrolled asthma are characterized by a lower capacity to generate these protective mediators 48, 49 . During the resolution of allergic airway inflammation, exogenous RvE1 resulted in more production of LXA 4 and inhibited the production of the leukocyte chemoattractant and secretagogue LTB 4 . Notably, both RvE1 and LTB 4 can interact with the LTB 4 receptor BLT-1, with RvE1 serving as a receptor antagonist 50 . In addition to its potent pro-resolution signals in airway inflammation 24, 47 , LXA 4 can also block LTB 4 -mediated responses in leukocytes 51 . The stable lipoxin analog ATLa resulted in significantly lower BALF leukocyte numbers and IL-17 concentrations, but the mechanism by which ATLa promoted resolution was distinct from that of RvE1-mediated regulation of IL-23 production, which suggests that IL-17 production is 'downstream' of IL-23. These results show that two classes of pro-resolution lipid mediators target IL-17 by distinct mechanisms to promote resolution.
In summary, RvE1 is a potent regulator of both the initiation and resolution of complex airway inflammation. To promote resolution, RvE1 decreased production of the proinflammatory cytokines IL-23, IL-6 and IL-17 and increased production of the counter-regulatory mediators IFN-g and LXA 4 . The regulation of adaptive immune responses by RvE1 indicates important pathological functions for IL-23 and T H -17 cells in the persistent and unrestrained immune responses of asthma and other chronic inflammatory diseases.
METHODS
Sensitization and challenge protocols. Male FVB mice 5-7 weeks of age (Charles River Laboratories) were housed in isolation cages in viral antibodyfree conditions. Mice were fed a standard diet (Laboratory Rodent Diet 5001; PMI Nutrition International) containing no less than 4.5% total fat with 0.26% omega-3 fatty acids and less than 0.01% C20:4. After approval by the institutional review board of Harvard Medical Area (protocol 03618), mice were sensitized by intraperitoneal injection on days 0 and 7 of 10 mg OVA (Grade III; Sigma) plus 1 mg aluminum hydroxide as adjuvant (Sigma) in 0.2 ml saline. On days 14, 15, 16 and 17, mice received aerosol challenge with 6% (wt/vol) OVA for 25 min per day. For analysis of inflammation development, some mice received the methyl ester form of RvE1 (5S,12R,18R-tri-hydroxy-6Z,8E,10E,14Z,16E-eicosapaentaenoic acid; 100 ng) or vehicle (0.1% (vol/vol) ethanol) in saline by intravenous injection 30 min before OVA aerosol challenge on days 14, 15, 16 and 17. This dose of RvE1 was chosen on the basis of its regulation of mouse peritoneal inflammation 10 . For analysis of inflammation resolution, some mice received RvE1 methyl ester (50 ng or 100 ng), the LXA 4 Measurement of lung resistance. For measurement of airway hyperresponsiveness, anesthetized mice were mechanically ventilated with a flexiVent (SciReq) and aerosolized methacholine (0, 1, 3, 10, 30 and 100 mg/ml) was delivered in-line through the inhalation port for 10 s. Lung resistance was determined as the mean of ten measurements obtained for each concentration of methacholine and is reported as the percent increase from baseline (PBS nebulization). No BALF or histological analysis was done for mice undergoing measurement of airway hyper-responsiveness.
Allergen-initiated respiratory inflammation. Mouse lungs were fixed in 10% (vol/vol) buffered formalin and were embedded in paraffin for staining with hematoxylin and eosin and with periodic acid-Schiff reagent (Sigma). Samples of cell-free BALF (centrifuged for 10 min at 2,000g) were assigned codes to mask their identity and cytokines were measured in aliquots by bead array (Pierce Biotechnology); lipid mediators were measured by enzyme-linked immunoassay (ELISA; LTB 4 , cysteinyl leukotrienes and PGD 2 (Cayman Chemical), and LXA 4 (Neogen)). Cells in BALF were resuspended in PBS and counted with a hemocytometer. Cytospins were done by cytocentrifugation (265g; StatSpin). Cells were stained with Wright-Giemsa stain (Sigma) for quantification of leukocyte subsets; 200 or more cells per slide were counted. Total serum immunoglobulin E was measured by ELISA (BD Biosciences).
Intracellular cytokine flow cytometry. Single-cell suspensions of lung, mediastinal lymph nodes and spleen were generated by passage of tissues through a 70-mm filter (BD Pharmingen). Samples were enriched for lung lymphocytes with Ficoll (Sigma). Cells were incubated for 4 h at 37 1C in vitro with phorbol 12-myristate 13-acetate (50 ng/ml; Sigma) and ionomycin (1 mg/ml; Sigma) plus GolgiStop (BD-Pharmingen). Fc receptors were blocked with anti-CD16/32 (MM 7300; Caltag), followed by cell surface staining with phycoerythrin-indodicarbocyanine-anti-CD4 (GK1.5; eBiosciences). Cells were then resuspended in fixation-permeabilization solution (Cytofix/Cytoperm; BD Pharmingen), and intracellular staining was done at 4 1C with fluorescein isothiocyanate-anti-IL-17A (eBio17B7; eBiosciences) and phycoerythrin-anti-IFN-g (XMG1.2; Caltag/Invitrogen). A FACSCalibur (Becton Dickson) was used for flow cytometry and data were analyzed with FloJo software (Tree Star).
Generation and purification of BMDCs. Femurs and tibiae of FVB mice were opened at both ends and bone marrow cells were extruded with ice-cold RPMI-1640 medium and passed through a 70-mm filter. Cells were cultured for 7 d at a density of 1 Â 10 6 cells per ml with IL-4 (1 ng/ml) and granulocyte-monocyte colony-stimulating factor (10 ng/ml; R&D Systems) in RPMI-1640 complete medium (10% (vol/vol) FCS and 2% (vol/vol) penicillin-streptomycin); the medium was changed every other day. On day 7, CD11c + BMDCs were further purified from nonadherent cells with anti-CD11c-coated magnetic beads according to the manufacturer's instructions (Miltenyi Biotech). The purity of the cells was assessed by flow cytometry to be over 93%. BMDCs were plated
